NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Mallinckrodt plc (MNK). Our investigation concerns whether Mallinckrodt has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On May 1, 2019, the Wall Street Journal published an article titled, “Government to File Complaint After Mallinckrodt Unit Is Accused of Bribery to Drive Drug Sales.” The article asserts that Questcor, which Mallinckrodt acquired in 2014, “defrauded government health-care plans by illegally marketing H.P. Acthar Gel.” The article further states that the company “stands accused of paying doctors kickbacks through bribes, consulting agreements and speaking fees if they prescribed Acthar.”
On this news, Mallinckrodt’s share price fell by more than 16%, closing at $15.29 on May 1, 2019.
If you purchased or otherwise acquired Mallinckrodt shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Mallinckrodt please go to http://www.bespc.com/mnk/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.